Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

14.31 -6.84

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.14

Max

15.36

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+91.56% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	130M 1.3B
Ouverture précédente	21.15
Clôture précédente	14.31

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 août 2026, 23:56 UTC

Chubb Ltd shares are modestly higher in after-market trading. No specific company news was identified to explain this movement.

20 août 2026, 23:56 UTC

Centene Corp. shares are higher in after-market hours, recovering slightly following three consecutive lower sessions. No specific news has been identified.

20 août 2026, 23:56 UTC

Correlated Moves

Hancock Whitney Corp shares were little changed after hours, following a session where the Russell 2000 Index gained slightly. The stock has declined for six straight sessions.

20 août 2026, 23:56 UTC

Lexicon Pharmaceuticals Inc shares are rising in after-market trading, showing positive momentum despite being below their 20-day moving average. No specific news was identified.

20 août 2026, 23:56 UTC

Astronics Corp shares are higher in after-market hours, diverging from a broader market decline amid rising Treasury yields and geopolitical tensions.

20 août 2026, 23:56 UTC

Union Pacific Corp shares are higher in after-market trading, reflecting a recovery from earlier lows amid rising U.S. Treasury yields and oil prices.

20 août 2026, 23:56 UTC

Correlated Moves

ETF Constituents

iShares MSCI Canada ETF trades lower in after-market hours, impacted by negative returns from key holdings CNQ and KGC, despite positive USD/CAD movement.

20 août 2026, 23:56 UTC

Energy Recovery Inc's shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

20 août 2026, 23:56 UTC

Correlated Moves

News

The Vanguard Mortgage-Backed Securities ETF remains roughly flat in after-market trading amid rising yields and concerns over high borrowing costs and geopolitical risks.

20 août 2026, 23:56 UTC

Old National Bancorp shares are lower in after-market hours following a volatile session, amid rising U.S. Treasury yields and geopolitical tensions.

20 août 2026, 23:56 UTC

LyondellBasell Industries NV shares are trading higher in after-market hours. The move comes amid rising U.S. Treasury yields and geopolitical tensions.

20 août 2026, 23:56 UTC

Antero Resources Corp. experienced routine trading activity after market hours, remaining roughly flat. The stock is positioned above its 20-day moving average.

20 août 2026, 23:56 UTC

Correlated Moves

Synchrony Financial shares are higher in after-market trading, though they remain below their 20-day moving average after five consecutive lower daily closes.

20 août 2026, 23:56 UTC

Amplitude Inc shares are higher in after-market hours, though no specific news was identified. The stock has performed well since July 21.

20 août 2026, 23:56 UTC

Yeti Holdings Inc. shares traded roughly flat in after-market hours, remaining near the lower end of their one-month range amid a weaker performance backdrop.

20 août 2026, 23:56 UTC

DTE Energy Co. shares are lower in after-market trading, continuing a decline amid rising U.S. Treasury yields and increasing oil prices.

20 août 2026, 23:56 UTC

CoStar Group Inc shares are higher in after-market trading, remaining above their 20-day moving average despite no specific news identified.

20 août 2026, 23:56 UTC

Comstock Resources Inc. shares are trading higher in after-market hours, amid rising U.S. Treasury yields and increasing oil prices. No specific news was identified.

20 août 2026, 23:56 UTC

Immunovant Inc shares are lower in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

20 août 2026, 23:56 UTC

Aptiv PLC shares are trading higher in after-market hours, recovering from an initial dip. No specific news was identified to explain the movement.

20 août 2026, 23:56 UTC

Enovix Corp shares were roughly flat in after-market hours. The asset remains significantly lower compared to its performance over the past month.

20 août 2026, 23:56 UTC

American Express shares are trading higher in after-market hours, despite remaining below their 20-day moving average and near the lower end of their one-month range.

20 août 2026, 23:56 UTC

Allstate Corp shares traded roughly flat in after-market hours amid rising U.S. Treasury yields and ongoing geopolitical tensions related to U.S.-Iran relations.

20 août 2026, 23:56 UTC

Correlated Moves

Macro News

ETF Constituents

KOSPI rises significantly, bolstered by financial shares, while after-market trading shows gains for the Financial Select Sector SPDR Fund amid rising crude oil prices.

20 août 2026, 23:56 UTC

United States Oil Fund LP is trading lower in after-market hours, continuing a decline since Thursday's close amid mixed global equity performance.

20 août 2026, 23:56 UTC

Correlated Moves

Macro News

ETF Constituents

The iShares MSCI Japan ETF is higher in after-market trading, reflecting a rebound in the Japanese stock market despite negative USD/JPY impacts.

20 août 2026, 23:56 UTC

Social Media

Alibaba Group Holding Ltd shares are lower in after-market trading, currently at $130.29, facing resistance at $132 amid a recent decline in market sentiment.

20 août 2026, 23:56 UTC

ETF Constituents

OSIS led declines among Vanguard Information Technology ETF holdings, while the ETF traded little changed in after-market hours following mixed global equity performance.

20 août 2026, 23:56 UTC

Horace Mann Educators Corp shares are lower in after-market trading, continuing a decline since Thursday's close amid rising Treasury yields and geopolitical tensions.

20 août 2026, 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

91.56% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 91.56%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.